Journal: mAbs

Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

doi: 10.1080/19420862.2018.1486946

Figure Lengend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

Article Snippet: Human breast cancer cell line BT-474 (HTB-20), MDA-MB-175VII (HTB-25), SK-BR-3(HTB-30) and HCC1419(CRL-2326) are HER2-positive cell lines, which were obtained from the ATCC, and HCC1419 is trastuzumab-resistant human breast cancer cell line.

Techniques: Activity Assay

Journal: BMC Cancer

Article Title: Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications

doi: 10.1186/1471-2407-3-13

Figure Lengend Snippet: Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the BT-474 breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at

Article Snippet: Seven MCF-7 variants (MCF-7-MVLN, MCF-7-ATCC, MCF-7-MF, MCF-7-MG, MCF-7-R, MCF-7-R-F3 and MCF-7-R-D4) were analyzed together with BT-474 breast cancer cells.

Techniques: RNA Expression, Expressing

Journal: International Journal of Nanomedicine

Article Title: Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

doi: 10.2147/IJN.S144184

Figure Lengend Snippet: Expression of HER2 in breast cancer cells, analyzed by flow cytometry. Notes: Representative fluorescence-activated cell sorting analysis of ( A ) MDA-MB-361 and ( B ) BT-474 cells tested by ALDEFLUOR assay. In the right image (ALDH+ DEAB), cells incubated with ALDH substrate (BAAA) and the specific inhibitor of ALDH, DEAB, were used to establish the baseline fluorescence of these cells (R1) and to define the ALDEFLUOR-positive region (R2). ( C ) Percentage of HER2 positively stained cells in breast cancer cells. ( D ) HER2 mean fluorescence intensity in breast cancer cells. Data are expressed as mean ± SD (n=3). ** P <0.01. Abbreviations: ALDH, aldehyde dehydrogenase; BAAA, BODIPY-aminoacetaldehyde; DEAB, diethylaminobenzaldehyde.

Article Snippet: Human breast cancer cell lines BT-474 and MDA-MB-361 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Expressing, Flow Cytometry, Fluorescence, FACS, Incubation, Staining

Journal: International Journal of Nanomedicine

Article Title: Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

doi: 10.2147/IJN.S144184

Figure Lengend Snippet: Cell proliferation assay. Notes: ALDH+ and ALDH− breast cancer cells were seeded in 96-well plates with a density of 1×10 4 cells per well overnight. The cells were incubated with the nanoparticles or salinomycin for 72 h, and cell viability was evaluated using the CCK-8 assay. ( A ) MDA-MB-361 ALDH+, ( B ) MDA-MB-361 ALDH−, ( C ) BT-474 ALDH+, and ( D ) BT-474 ALDH−. Data are expressed as mean ± SD (n=3). Abbreviations: ALDH, aldehyde dehydrogenase; CCK-8, Cell Counting Kit-8; Sali-NP, salinomycin-loaded polymer-lipid nanoparticles; Sali-NP-HER2, salinomycin-loaded polymer–lipid hybrid anti-HER2 nanoparticles.

Article Snippet: Human breast cancer cell lines BT-474 and MDA-MB-361 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Proliferation Assay, Incubation, CCK-8 Assay, Cell Counting

Journal: International Journal of Nanomedicine

Article Title: Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

doi: 10.2147/IJN.S144184

Figure Lengend Snippet: The IC 50 values of salinomycin and nanoparticles in breast cancer cells

Article Snippet: Human breast cancer cell lines BT-474 and MDA-MB-361 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques:

Journal: International Journal of Nanomedicine

Article Title: Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

doi: 10.2147/IJN.S144184

Figure Lengend Snippet: Effect of treatments on the percentage of CSCs. Notes: Effect of the treatments on the proportion of CSCs in breast cancer cells, as reflected by the tumorsphere formation rate ( A and B ) and the proportion of ALDH+ cells ( E and F ). Representative images of tumorspheres formed by ( C ) MDA-MB-361 cells and ( D ) BT-474 cells are shown. The rate of tumorsphere formation is defined as the number of tumorspheres formed in 7 days in the treatment group divided by the number of tumorspheres formed in 7 days in the untreated group; the rate of tumorsphere formation in the untreated group is used as a control and defined as 100%. The two groups were compared by one-way ANOVA with the Newman–Keuls method. Data are expressed as mean ± SD (n=6). * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: ANOVA, analysis of variance; ALDH, aldehyde dehydrogenase; CSCs, cancer stem cells; Sali-NP, salinomycin-loaded polymer–lipid nanoparticles; NP-HER2, polymer–lipid anti-HER2 nanoparticles; Sali-NP-HER2, salinomycin-loaded polymer–lipid hybrid anti-HER2 nanoparticles.

Article Snippet: Human breast cancer cell lines BT-474 and MDA-MB-361 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques:

Journal: International Journal of Nanomedicine

Article Title: Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells

doi: 10.2147/IJN.S144184

Figure Lengend Snippet: In vivo antitumor assay in mice bearing subcutaneous BT-474 tumors. Notes: BT-474 tumors reached ~50 mm 3 in size by day 10. From day 10, mice were injected with nanoparticles (7.5 mg salinomycin/kg, i.v.) through the tail vein, and salinomycin (7.5 mg salinomycin/kg) dissolved in ethanol was administered by intraperitoneal injection. Therapy was given nine times on alternate days (indicated by arrows), and tumor volume was calculated. ( A ) Tumor growth curve. ( B ) Excised tumors. ( C ) The excised tumors were weighed at the end point. On day 28, the effect of the drug treatments on the CSC proportion in BT-474 tumors in vivo was evaluated by ( D ) the rate of tumorsphere formation and ( E ) the proportion of ALDH+ cells from the excised tumors. ( F ) Representative images of tumorspheres from ( D ) are shown. The two groups were compared by one-way ANOVA with the Newman–Keuls method. Data are expressed as mean ± SD (n=8). * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: ANOVA, analysis of variance; ALDH, aldehyde dehydrogenase; CSC, cancer stem cell; i.v., intravenous; Sali-NP, salinomycin-loaded polymer–lipid nanoparticles; NP-HER2, polymer–lipid anti-HER2 nanoparticles; Sali-NP-HER2, salinomycin-loaded polymer–lipid hybrid anti-HER2 nanoparticles.

Article Snippet: Human breast cancer cell lines BT-474 and MDA-MB-361 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: In Vivo, Injection

Journal: Molecular Cancer

Article Title: Phosphorylation of Ser 78 of Hsp27 correlated with HER-2/ neu status and lymph node positivity in breast cancer

doi: 10.1186/1476-4598-6-52

Figure Lengend Snippet: Effect of heregulin α1 (HRG α1) and p38 MAPK inhibitor (SB 203580) on Hsp27 phosphorylation . Cultures of cells from the BT474 breast cancer cell line were treated with HRG α1 for 10 and 30 min (A) or SB 203580 for 10 hours (B) and total cell lysates were extracted using M-PER reagent (Pierce). Equal amounts of proteins (20 μg) were separated by SDS-PAGE and transferred onto PVDF membrane. The membranes were blocked for 1 hour, followed by being probed with the respective primary antibodies (anti-Hsp27, anti-pSer 15 , anti-pSer 78 and anti-pSer 82 ), and HRP-conjugated secondary antibody. The signals were captured and their intensities were detected as described in Figure 2. The phosphorylation levels of pSer 15 , pSer 78 and pSer 82 were expressed as the ratios of intensity probed with phosphorylation site-specific antibody to the intensity probed with anti-Hsp27. Data with ± SD represents the average of triplicate experiments. C: control; SB: inhibitor SB203580. For the control of HRG-treated cells, untreated cells were cultured for 10 and 30 min and equal amounts of cellular proteins from both time intervals were mixed and used as control. For the control of inhibitor-treated cells, cells were treated with DMSO for 10 hours and cellular proteins were used as the control. * p < 0.05 (student t -test)

Article Snippet: The human BT474 breast cancer cell line was obtained from American Type Culture Collection, and maintained in modified Dulbecco's medium (HybriCare) supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere of 5% CO 2 in an incubator.

Techniques: SDS Page, Cell Culture

Journal: International Journal of Biological Sciences

Article Title: Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating miR-125a/BRD4 axis

doi: 10.7150/ijbs.58916

Figure Lengend Snippet: The potential diagnostic and prognostic value of circBCBM1. (A) RT-qPCR analysis of circBCBM1 expression in 231-BR cells versus other breast cancer cells (MDA-MB-231, BT-474 and T47D). The relative expression level was normalized to that of MDA-MB-231 cells. (B and C) RT-qPCR analyses of circBCBM1 expression level in tissue (B) and plasma (C) samples. For (B), NBT, adjacent normal breast tissues, n = 13; BC, breast cancertissues, n = 13; BCBM, breast cancer brain metastasis tissues, n = 6. For (C), BC, breast cancer plasmas, n = 20; BCBM, breast cancer brain metastasisplasmas, n = 20. Data are presented as means ± SEM (A-C). (D) Kaplan-Meier analysis for brain metastasis-free survival (BMFS) of 53 BCBM patients. Patients were divided into two groups based on the expression of circBCBM1 in the patients' primary tumors. P- value was calculated using the log-rank test.

Article Snippet: Breast cancer cell line BT-474 and T47D were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco, Vienna, Austria) with 5% CO 2 at 37 °C.

Techniques: Diagnostic Assay, Quantitative RT-PCR, Expressing

Journal: Breast Cancer Research : BCR

Article Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

doi: 10.1186/bcr2936

Figure Lengend Snippet: Phosphorylated levels of β1 downstream kinases are increased upon acquisition of resistance to lapatinib (L) . ( A ) Parental (P) BT474 and ( B ) HCC1954 cells resistant to lapatinib (LRes), trastuzumab (TRes), and combination (LTRes) treatment strategies were developed by long-term exposure in 2D. Protein extracts were probed for β1, pHER2, pFAK, and pSrc, as well as totals.

Article Snippet: The human breast cancer cell line BT474 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously described [ ].

Techniques:

Journal: Breast Cancer Research : BCR

Article Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

doi: 10.1186/bcr2936

Figure Lengend Snippet: β1 blockade overcomes lapatinib resistance in BT474 cells in 3D culture . ( A ) Parental and LRes cells were plated on lrECM and treated ± lapatinib. ( B ) The β1 inhibitory antibody AIIB2--or IgG control--was applied to parental and LRes cells on Day 0 of plating on lrECM and allowed to grow for 12 days. ( C ) Parental and LRes cells were plated in lrECM with appropriate inhibitors, allowed to grow for five days, stained with Ki67 antigen or TUNEL labeling, and imaged. ( D ) 3D cultures of BT474 parental and LRes cells treated with AIIB2 or IgG were allowed to propagate for five days, then harvested for protein and immunoblotting. Densitometry measurements were normalized to total levels--except β1, which was normalized to β-actin--and are representative of three independent experiments. ( E ) The FAK inhibitor PF 573228 was applied to parental and LRes cells on Day 0 of plating on lrECM and cultures were allowed to grow for 12 days.

Article Snippet: The human breast cancer cell line BT474 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously described [ ].

Techniques: Staining, TUNEL Assay, Labeling, Western Blot

Journal: Breast Cancer Research : BCR

Article Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

doi: 10.1186/bcr2936

Figure Lengend Snippet: Percent growth inhibition of cells in response to HER-targeted therapies

Article Snippet: The human breast cancer cell line BT474 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously described [ ].

Techniques: Inhibition

Journal: Breast Cancer Research : BCR

Article Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

doi: 10.1186/bcr2936

Figure Lengend Snippet: HER2 and the β1 pathway play alternate roles in resistance to lapatinib-containing regimens, in comparison to trastuzumab . ( A ) Parental, LRes, and TRes cells were plated on lrECM in the presence of lapatinib and/or trastuzumab and assayed for response. ( B ) 3D cultures of parental, LRes, and TRes BT474 cells were harvested for protein and probed for phosphorylated and total HER receptors.

Article Snippet: The human breast cancer cell line BT474 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously described [ ].

Techniques:

Journal: Breast Cancer Research : BCR

Article Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

doi: 10.1186/bcr2936

Figure Lengend Snippet: β1 inhibition impedes colony grow of BT474 LRes and LTRes cells, but not parental or TRes . ( A ) Parental, LRes, LTRes, and TRes cells were plated in lrECM, subjected to HER2 and/or β1 inhibitors on Day 0, and propagated for 10 to 12 days. ( B ) The Hs_ITGB1_5 siRNA was validated both in 2D and 3D (top), transfected at 40 nMsi into parental, LRes, LTRes, and TRes cells, which were then grown on lrECM for 10 days (bottom).

Article Snippet: The human breast cancer cell line BT474 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained as previously described [ ].

Techniques: Inhibition, Transfection

Journal: Oncoscience

Article Title: FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells

doi:

Figure Lengend Snippet: A. Effects of FS-93 on cell proliferation. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 72 h. Cell viability was assessed with SRB assay. Bars represent means±SD. B. Effects of FS-93 on degradation of client onco-proteins. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 24 h. Cell lysates were prepared and analyzed with immunoblotting.

Article Snippet: Human breast cancer cell line BT-474 was obtained from American Type Culture Collection (Manassas, VA).

Techniques: Sulforhodamine B Assay, Western Blot

Journal: Oncoscience

Article Title: FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells

doi:

Figure Lengend Snippet: A ., B. Effects of FS-93 on cell cycle distribution. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 24 h. Cell cycle distribution was analyzed by FACS after propidium iodide staining. Representative images A. and quantification results B. were presented. Bars represent means±SD. C. Impacts of FS-93 on G2/M transition regulators. BT-474, NCI-H3122 and EBC-1 cells were treated with FS-93 at 25, 50 and 100nM or NVP-AUY922 at 100 nM for 24 h and cells lysates were immunoblotted with the indicated antibodies.

Article Snippet: Human breast cancer cell line BT-474 was obtained from American Type Culture Collection (Manassas, VA).

Techniques: Staining

Journal: Oncoscience

Article Title: FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells

doi:

Figure Lengend Snippet: A. Effects of FS-93 on apoptosis induction. BT-474, NCI-H3122 and EBC-1 cells were treated with DMSO or FS-93 at 100 nM for 12, 24, 48 and 72h. Apoptosis was determined with annexin-V/PI assay. Bars represent means±SD. B. Impacts of FS-93 on apoptotic proteins. BT-474 cells were treated with DMSO or FS-93 at 100 nM for 12, 24, 48 and 72h and analyzed by immunoblotted with the indicated antibodies.

Article Snippet: Human breast cancer cell line BT-474 was obtained from American Type Culture Collection (Manassas, VA).

Techniques:

Journal: Theranostics

Article Title: Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer

doi: 10.7150/thno.27798

Figure Lengend Snippet: PDGFRβ aptamer inhibits mesenchymal TNBC cell migration and invasion. (A) MDA-MB-231 and BT-549 (PDGFRβ-positive) cell migration toward 10% FBS was analyzed by transwell migration assay in the presence of 200 nM Gint4.T or Scr for 24 h. (B) Invasion of MDA-MB-231 and BT-549 cells toward 10% FBS through Matrigel was carried out in the presence of 200 nM Gint4.T or Scr for 72 h. (C) Migration and (D) invasion of control BT-474 (PDGFRβ-negative) cells were analyzed as in (A) and (B), respectively. (A-D) Photographs of a representative experiment are shown. Magnification 10 ×, scale bar = 200 μm. Data are presented as percentage of migrated or invaded cells in the presence of Gint4.T compared with Scr control. Bars depict mean ± SD of three independent experiments. *** P < 0.001.

Article Snippet: Growth conditions for human TNBC MDA-MB-231 and BT-549 cells, and HER2-positive breast cancer BT-474 cells (American Type Culture Collection, Manassas, VA) were previously reported .

Techniques: Migration, Transwell Migration Assay

Journal: Theranostics

Article Title: Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer

doi: 10.7150/thno.27798

Figure Lengend Snippet: NIR-Gint4.T aptamer specifically binds to human PDGFRβ-positive TNBC cells. (A) Left panel: Binding curve of NIR-Gint4.T on MDA-MB-231 cells for calculation of the apparent K d of aptamer-cell interaction. Binding was analyzed using flow cytometry. The nonspecific binding value for NIR-Scr sequence was subtracted from every data point. Bars depict mean ± SD of three independent experiments. Right panel: MDA-MB-231 cells were mock-treated or incubated with 25 nM NIR-Gint4.T prior to incubation with 50 nM EC-PDGFRβ for 30 min at RT, and binding was analyzed by flow cytometry. (B) Control BT-474 (PDGFRβ-negative) cells were mock-treated or incubated with 500 nM NIR-Gint4.T or NIR-Scr and binding was analyzed by flow cytometry. (C) Following 5 min incubation with 500 nM NIR-Gint4.T or NIR-Scr, MDA-MB-231 cells were fixed and labeled with anti-PDGFRβ antibody without permeabilization, visualized by confocal microscopy and photographed. Representative 2D and 3D images constructed using Z-scan are shown. NIR-aptamer, PDGFRβ and nuclei are visualized in red, green and blue, respectively. Co-localization results appear yellow in the merged images. (D) Following 5 min incubation with NIR-Gint4.T or NIR-Scr, BT-474 cells were visualized by confocal microscopy and photographed. (A-D) At least three independent experiments were performed. All digital images were captured at the same setting to allow direct comparison of staining patterns. Magnification 63 ×, scale bar = 20 μm. DAPI: 4′,6-Diamidino-2-phenylindole; K d : dissociation constant; MFI: mean fluorescence intensity; NIR: near-infrared; PDGFRβ: platelet-derived growth factor receptor β; 3D: three-dimensional; 2D: two-dimensional.

Article Snippet: Growth conditions for human TNBC MDA-MB-231 and BT-549 cells, and HER2-positive breast cancer BT-474 cells (American Type Culture Collection, Manassas, VA) were previously reported .

Techniques: Binding Assay, Flow Cytometry, Sequencing, Incubation, Labeling, Confocal Microscopy, Construct, Staining, Fluorescence, Derivative Assay

Journal: Theranostics

Article Title: Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer

doi: 10.7150/thno.27798

Figure Lengend Snippet: Selective imaging of PDGFRβ-positive tumors by NIR-Gint4.T. (A) Nude mice bearing MDA-MB-231 xenografts were i.v. injected with 1 nmol of either NIR-Gint4.T or NIR-Scr and analyzed with FMT at the indicated times. Top: Representative volume renderings taken at the same color gating for NIR-Gint4.T and NIR-Scr (n = 5)-injected mice are shown. Bottom, left: The amount of fluorescence (pmol) was quantified in specific VOIs encompassing the tumor in the animal. Bars depict mean ± SD. *** P < 0.001; ** P < 0.01; * P < 0.05 (n = 5). Bottom, right: Shown are representative images of the tumors excised from mice 24 h post NIR-Gint4.T and NIR-Scr injection. (B) Mice bearing PDGFRβ-positive (left flank) or PDGFRβ-negative (right flank) tumors were i.v. injected with 1 nmol of either NIR-Gint4.T (MDA-MB-231 and BT-474 tumors) or NIR-Scr (MDA-MB-231 tumors) and analyzed with FMT at 2 h following injection. (C) Representative images of FMT obtained 2 h after injection of 100 pmol NIR-Gint4.T in the absence (left) or in the presence (right) of pretreatment with a large excess of unlabeled Gint4.T. Notably, the ten-fold reduced amount of NIR-Gint4.T is efficacious to detect the tumor. (D) Analyses of the in vitro serum stability of the NIR-RNAs. Denaturing PAGE of NIR-Gint4.T and NIR-Scr following incubation with 80% human serum at the indicated times. Depicted results represent one of three typical experiments performed. Gint4.T and Scr contain 2´F-Py in all the sequence to increase nuclease resistance. (E) Plasma pharmacokinetic profile of NIR-Gint4.T aptamer. Concentration of aptamer is shown as a function of time following a single i.v. injection in Balb/c mice. Data are presented as the mean ± SD (n = 3 for each administration). Note that we obtained a pharmacokinetic profile of unlabeled Gint4.T aptamer superimposable to that of NIR-Gint4.T. Em: emission; Ex: excitation; NIR: near-infrared; PDGFRβ: platelet-derived growth factor receptor β.

Article Snippet: Growth conditions for human TNBC MDA-MB-231 and BT-549 cells, and HER2-positive breast cancer BT-474 cells (American Type Culture Collection, Manassas, VA) were previously reported .

Techniques: Imaging, Injection, Fluorescence, In Vitro, Incubation, Sequencing, Concentration Assay, Derivative Assay